Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas

BACKGROUND/AIMS: Rituximab is known to be associated with high hepatitis B virus (HBV) reactivation rate in patients with resolved HBV infection and hematologic malignancy. However, data regarding HBV reactivation (HBVr) in rheumatic patients receiving rituximab is limited. To assess the HBVr rate i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Ting-Yuan, Lin, Yen-Chun, Tseng, Tai-Chung, Yang, Hung-Chih, Kao, Jui-Hung, Cheng, Chiao-Feng, Lee, Tai-Ju, Huang, Shang-Chin, Lu, Cheng-Hsun, Li, Ko-Jen, Hsieh, Song-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018307/
https://www.ncbi.nlm.nih.gov/pubmed/36268584
http://dx.doi.org/10.5009/gnl210551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018307/
https://www.ncbi.nlm.nih.gov/pubmed/36268584
http://dx.doi.org/10.5009/gnl210551

Ejemplares similares